Home › Funds › Dorsey Asset Management, LLC › RPRX
Dorsey Asset Management, LLC position in RPRX
ROYALTY PHARMA PLC · Health Care
Dorsey Asset Management, LLC reported holding 2,456,528 shares of RPRX (ROYALTY PHARMA PLC) in its Q2 2026 13F filing — a position valued at US$137.7M, representing 8.82% of its reported portfolio and ranking #3 among its reported holdings. Dorsey Asset Management, LLC has disclosed RPRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Dorsey Asset Management, LLC's RPRX position evolved
Dorsey Asset Management, LLC first disclosed a stake in RPRX in Q3 2025 at 2,350,449 shares (US$82.9M). The position peaked in Q2 2026 at 2,456,528 shares, worth US$137.7M. Across 4 filings, Dorsey Asset Management, LLC increased the stake 2 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 2,456,528 shares valued at US$137.7M — an increase of 179,958 shares quarter over quarter..
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 2.35M | $82.92M | New |
| Q4 2025 | 2.26M | $87.31M | Reduce |
| Q1 2026 | 2.28M | $109.21M | Add |
| Q2 2026 | 2.46M | $137.74M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RPRX and 13F data
RPRX (ROYALTY PHARMA PLC) is a Health Care company. 49 other funds we track also report a position in RPRX — the largest reported positions include Swedbank AB (US$601.4M), Baillie Gifford & Co (US$561.6M), Caledonia (Private) Investments Pty Ltd (US$323.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RPRX
- Swedbank AB 10.73M sh · $601.44M · Q2 2026
- Baillie Gifford & Co 10.02M sh · $561.57M · Q2 2026
- Caledonia (Private) Investments Pty Ltd 5.78M sh · $323.85M · Q2 2026
- ROYAL LONDON ASSET MANAGEMENT LTD 4.32M sh · $242.20M · Q2 2026
- Patient Capital Management, LLC 3.60M sh · $201.79M · Q2 2026
- Regal Partners Ltd 2.45M sh · $137.25M · Q2 2026
- NEW SOUTH CAPITAL MANAGEMENT INC 2.39M sh · $133.78M · Q2 2026
- Clark Capital Management Group, Inc. 1.66M sh · $93.24M · Q2 2026
- HOMESTEAD ADVISERS CORP 1.66M sh · $92.92M · Q2 2026
- EVENTIDE ASSET MANAGEMENT, LLC 1.38M sh · $77.67M · Q2 2026
More on Dorsey Asset Management, LLC
FAQ
How long has Dorsey Asset Management, LLC held RPRX?
Dorsey Asset Management, LLC has disclosed RPRX holdings in 4 of the last 4 reported quarters, going back to Q3 2025.
What is Dorsey Asset Management, LLC's current position in RPRX?
As of Q2 2026, Dorsey Asset Management, LLC holds 2.46M shares of RPRX (ROYALTY PHARMA PLC), valued at $137.74M, representing 8.82% of its reported portfolio and ranking #3.
Has Dorsey Asset Management, LLC been buying or selling RPRX?
In the latest 13F filing (Q2 2026), Dorsey Asset Management, LLC increased its position in RPRX. The position peaked in Q2 2026 at 2.46M shares.
Which other funds hold RPRX?
Other major institutional holders of RPRX include Swedbank AB, Baillie Gifford & Co, Caledonia (Private) Investments Pty Ltd, among 49 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.